Back to today’s briefing

Story perspectives

Light Horse Therapeutics Secures $62M for Cancer Innovation

1/10/2025

40 7

Summary

Story summary

Light Horse Therapeutics, a San Diego biotech, has raised an impressive $62 million in Series A funding, spearheaded by Versant Ventures. In a groundbreaking partnership with Novartis, they received $25 million upfront, with the potential to earn up to $1 billion. Their innovative "function-first" strategy aims to revolutionize cancer drug discovery through precision genome editing.

1 of 1

Story summary

Light Horse Therapeutics, a San Diego biotech, has raised an impressive $62 million in Series A funding, spearheaded by Versant Ventures. In a groundbreaking partnership with Novartis, they received $25 million upfront, with the potential to earn up to $1 billion. Their innovative "function-first" strategy aims to revolutionize cancer drug discovery through precision genome editing.